NewLink Genetics to Host Its Third Quarter 2019 Conference Call on November 6, 2019
30 Octobre 2019 - 1:30PM
NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will
host its third quarter 2019 conference call and webcast at 8:30 AM
ET on Wednesday, November 6, 2019, to discuss its third
quarter financial results and provide an update on corporate
activities. There will also be a question and answer session
following the prepared remarks.
Investors and the general public are invited to
listen to a live audio webcast of the conference call, which can be
accessed five minutes prior to the start of the call by dialing
(855) 469-0612 (U.S.) or (484) 756-4268 (international). The
conference call will be webcast live and a link can be accessed
through the NewLink Genetics website at
https://edge.media-server.com/mmc/p/sm3cyp39. A replay of the call
will be available for two weeks from the date of the call and can
be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406
(international) and using the passcode: 3794399.
About NewLink Genetics
Corporation
NewLink Genetics is a clinical stage
biopharmaceutical company that has been focused on novel oncology
product candidates targeting indications with limited treatment
options. On September 30, 2019, NewLink announced its intent to
merge with Lumos Pharma, a private clinical-stage biopharmaceutical
company targeting rare and neglected diseases. At the close of the
proposed merger, the combined company will operate as Lumos Pharma
focused on lead product candidate, LUM-201 (ibutamoren), an oral
growth hormone (GH) secretagogue targeting pediatric growth hormone
deficiency (PGHD) and other rare endocrine disorders. If approved,
LUM-201 would represent the first orally administered growth
hormone stimulating therapy for PGHD, an established market where
daily recombinant human growth hormone injections represent the
current standard-of-care treatment regimen. For more information,
please visit www.NewLinkGenetics.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements of NewLink Genetics that involve substantial
risks and uncertainties. All statements contained in this press
release are forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. The words
“forecast,” “projected,” "guidance," "upcoming," "will," "plan,"
“intend,” "anticipate," "approximate," "expect," “potential,” or
the negative of these terms or other similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements include, among others, statements
about NewLink Genetics' financial guidance for 2019 and
beyond; results of its clinical trials for product candidates; its
timing of release of data from ongoing clinical studies; its plans
related to execution of clinical trials; plans related to moving
additional indications into clinical development; NewLink
Genetics' future financial performance, impact of management
changes, organizational restructuring, results of operations, cash
position and sufficiency of capital resources to fund its operating
requirements; statements about NewLink Genetics’ expectations
regarding the capitalization, resources and ownership structure of
the combined company; NewLink Genetics’ expectations regarding the
sufficiency of the combined company's resources to fund the
advancement of any development program or the completion of any
clinical trial; statements about the potential benefits of the
transaction; the expected completion and timing of the transaction
and other information relating to the transaction; expected costs
associated with termination benefits and financial impact of the
reduction in force, and any other statements other than statements
of historical fact. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that NewLink Genetics
makes due to a number of important factors, including (i) the risk
that the transaction may not be completed in a timely manner or at
all, which may adversely affect the NewLink Genetics’ business and
the price of the common stock of NewLink Genetics, (ii) the failure
to satisfy of the conditions to the consummation of the
transaction, including approval of the issuance of shares of
NewLink Genetics common stock in the transaction or the
contemplated reverse stock split, (iii) the occurrence of any
event, change or other circumstance that could give rise to the
termination of the merger agreement, (iv) the risk that the
definitive merger agreement may be terminated in circumstances that
require NewLink Genetics to pay a termination fee to Lumos Pharma;
(v) risks related to the ability to realize the anticipated
benefits of the transaction, including the risk that the businesses
will not be integrated successfully, (vi) the effect of the
announcement or pendency of the transaction on NewLink Genetics’
business relationships, operating results and business generally,
(vii) risks that the proposed transaction disrupts current plans
and operations, (viii) risks related to diverting management’s
attention from NewLink Genetics’ ongoing business operations, (ix)
other business effects, including the effects of industry, market,
economic, political or regulatory conditions, future exchange and
interest rates, and changes in tax and other laws, regulations,
rates and policies, (x) the uncertainties inherent in research and
development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for clinical
trials, regulatory submission dates, regulatory approval dates
and/or launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data, (xi)
the risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities; (xii)
risks related to cost reduction efforts; (xiii) NewLink Genetics’
workforce reduction costs may be greater than anticipated and the
workforce reduction may have an adverse impact on the NewLink
Genetics’ development activities: and (xiv) the outcome of any
legal proceedings that may be instituted against NewLink Genetics
related to the merger agreement or the transaction. Further risks
that could cause actual results to differ materially from those
matters expressed in or implied by such forward-looking statements
are discussed in "Risk Factors" and elsewhere in NewLink
Genetics' Quarterly Report on Form 10-Q for the quarter
ended June 30, 2019 and other reports filed with
the SEC. The forward-looking statements in this press release
represent NewLink Genetics’ views as of the date of this
press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink
Genetics' views as of any date subsequent to the date of this
press release.
Investor & Media Contact:
Lisa MillerDirector of Investor RelationsNewLink
Genetics515-598-2555lmiller@linkp.com
Source: NewLink Genetics Corporation
NewLink Genetics (NASDAQ:NLNK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
NewLink Genetics (NASDAQ:NLNK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024